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Lipid lowering agents have been repeatedly the objective of studies analysing their utilization and costs. The 
objective of this study was to evaluate the structure and development of consumption of hypolipidemic 
agents. 
Material and methods. Data concerning utilization of individual hypolipidemic drugs from 2002 to 2009 were 
obtained from the State Institute for Drug Control database and General Health Insurance Company – 
Karvina district database. Utilization of hypolipidemic drugs were stated in DDDs in correspondence with the 
ATC Classification, and the costs in CZK. Information on utilization is expressed in the number of DDD per 
1,000 inhabitants per 1 day (DID). 
Results. The utilization of fibrates slightly decreased, while statins an increase from 13.55 DID (2002) to 
60.10 DID (2009) was observed. The total utilization of hypolipidemic drugs in DID has been continuously 
increasing (32.34 DID in 2002, 76.30 DID in 2009). Hypolipidemic drugs take the 5th place in the Czech 
Republic from the standpoint of expenses. Atorvastatin has been number one since 2007. In the compared 
data from the Karvina district, an increased utilization of fibrates and decreased utilization of statins were 
observed. The most significant difference was noted in the utilization of ezetimibe (the utilization of which 
from 2006 to 2009 was 2-3 times higher than was the average in the Czech Republic). 
Conclusions. Increasing availability of hypolipidemics was noticed with some regional discrepancies and sex 
differences in consumption of this group of medicines. 
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